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Table 1
Patients
N¼30 (range)
Male pts 20
Median age, yrs 55 (22 - 72)
Median days on statin 190 (60 - 199)
Median KPS 85 (70 -100)
Median HCT-CI 1.5 (0 - 5)
CIBMTR Disease Risk _
Low 10
Intermediate 9
High 11
Diagnosis _
AML 8
CML/CMML 2
MDS/MPD 5
CLL/SLL 2
NHL/Hodgkin 11
Others 2
Chemorefractory 11
Prior autograft 5
10/10 HLA match 30
Conditioning _
RIC 16
Myeloablative 14
Peripheral blood graft 30
ABO mismatched 10
Female donor to male patient 10
Median infused CD34 cells/kg 4.1 x 106
Median infused CD3 cells/kg 33.2 x 107
Median Follow-up of survivors, days 222 (11-717)
Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149S138Between Sep 2010 and Oct 2012, target enrollment of 30
donor/recipient pairs was completed. Median donor age was
52.5 yrs (range 24-75). ATOR prophylaxis in healthy donors
(median duration 14 days [range 7-24]), was not associated
with any Gr 3-4 adverse events (AEs). Table 1 shows baseline
patient (pt) characteristics. No ATOR related Gr 2-4 AEs were
seen. Themedian time to ANC500/mL was 18 days (range 5-
25) and to platelets 20k/mL was 15 days (range 11-51). The
median day 100 chimerismwas 80.5% for T-cells and 100% for
myeloid cells. Respective numbers at day 180 are 100% and
100%. Among 29 evaluable pts (1 pt waiting to engraft), the
cumulative incidence (CI) of Gr II-IV and IIIeIV aGVHD at day
100 are 3.7 3.7% and 0% respectively. Respective, rates at
day 180 are 13 7.3% and 9.1 7.3%. CI of mild/moderate and
severe chronic GVHD at 1 year are 26 11.5% and 23.5 
10.7%, respectively. Only 2 pts had CMV reactivation. Non-
relapse mortality was 0% at day 100 and 5% at day 180. CI of
relapse at day 180 was 19.7%. 1-year progression-free and
overall survival estimates are 68% and 69%, respectively.
A two-pronged strategy of ATOR administration to both
donors and recipients of MRD alloHCT appears to be
a feasible, safe and effective method for aGVHD prophylaxis.
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of MichiganWe have recently described an algorithm combining
biomarkers and clinical characteristics that, at the onset of
acute GVHD symptoms, predicts outcomes such as treatment
response and non-relapse mortality (NRM). We have now
evaluated whether a combination of pre-HCT clinical char-
acteristics and a biomarker panel measured early post-HCT
can predict future GVHD.
From 2001-2011, we prospectively collected clinical data
and plasma samples from 393 patients receiving related
donor HCT at our institution. The cumulative incidence of
grade 2-4 GVHD by day 100 was 31% (n ¼ 121; median onset
¼ day 40). We divided patients randomly into a training set
(n¼264) to develop GVHD predictive algorithms using
logistic regression, and a validation set (n¼129) to test the
algorithms. There were no statistically signiﬁcant differences
in pre-HCT clinical parameters between the 2 sets. We
measured 4 GVHD biomarkers (IL-2Ra, TNFR1, elaﬁn, and
REG3a) on post-HCT day 7 plasma samples by ELISA.
Grade 2-4 GVHD onset within 2 months of HCT served
as the predictive endpoint. We developed 3 predictive
models for GVHD in the training set: 5 validated clinical
risk factors alone (patient age, myeloablative conditioning
[MA]), HLA-match, GVHD prophylaxis, graft source, use of
TBI); the 4 biomarker panel alone; and a combination of all
9 clinical and biomarker parameters. We compared all 3
models at a speciﬁcity of 50% for their respective sensitiv-
ities. Clinical factors alone provided 51% sensitivity, 4
biomarkers alone provided 66% sensitivity, and all 9
parameters combined provided 77% sensitivity (combined
vs. clinical model, P < .001; vs. biomarker model, P ¼ .07).
The combined model provided similar sensitivity in the
validation set (75%) which allowed us to combine the 2 sets
for further analyses.
We used the algorithm to stratify patients as high
(N¼211) or low risk (n¼182) for developing GVHD. High risk
patients were twice as likely to develop grade 2-4 GVHD
(Figure 1A; 38% vs. 20%, P < .001) which developed almost 1
month earlier than in the low risk group (median day ¼ 39
vs. 65). The greater incidence of GVHD in high risk patients
resulted in signiﬁcantly greater NRM by day 180 post-HCT
(Figure 1B; 12% vs. 3%; P ¼ .001). The relapse rate was
identical in both groups (24%), thus overall survival (OS) was
signiﬁcantly better in the low risk group (84% vs. 73%, P ¼
.004). The differences between high and low risk patients
remained signiﬁcant at 1-yr post-HCT for NRM (17% vs. 6%, P
< .001) and OS (61% vs. 72%, P ¼ .01).
In conclusion, combining a panel of 4 biomarkers at day 7
post-HCT and 5 pre-HCT clinical parameters produced the
best algorithm to predict GVHD following related donor HCT.
The algorithm successfully stratiﬁed patients into high and
low risk groups for GVHD, NRM and OS. We hypothesize the
use of such an algorithm may permit preemptive therapy for
patients who are at greatest risk in the early transplant
course.
Figure 1.
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Introduction:We have created a non-human primate (NHP)
model of GvHD. Here we determined whether mTOR inhi-
bition with sirolimus and CD28:CD80/86 costimulation
blockade with belatacept could combine synergistically to
prevent this disease.
Methods: Rhesus macaques were irradiated (9.6 Gy), and
then transplanted with GCSF-mobilized PBSC from a hap-
loidentical donor. Recipients were treated with either siro-
limus alone, belatacept alone or combination therapy.
Clinical GvHD was monitored using an NHP grading scale
and multiparameter ﬂow cytometric analysis (MFC) was
performed.
Results: Untreated controls (n ¼ 5) developed rapid, severe
aGvHD and succumbed rapidly (MST ¼ 7 days). Treatment
with either sirolimus or belatacept alone partially protected
against GvHD. Sirolimus-treated recipients (n ¼ 6) devel-
oped predominantly GI disease and had an MST of 14 days
(Figure 1A). Recipients treated with belatacept alone (n ¼ 3)
developed primarily liver aGvHD and had an MST of 11 days.
In striking contrast, recipients treated with combined siro-
limus + belatacept (n ¼ 5) demonstrated neither uncon-
trolled diarrhea nor hyperbilirubinemia at the timed
terminal analysis (1 month post-transplant).
We used MFC to measure the immunologic consequences
of sirolimus and belatacept on T cell proliferation (Ki-67) and
cytotoxity (granzyme B). While untreated aGvHD was asso-
ciated with rampant CD8+ proliferation (with 83% Ki-67+
CD8+ T cells vs 4.7% pre-transplant), sirolimus or belatacept
monotherapy partially controlled proliferation (35% and 65%
Ki-67+ with sirolimus or belatacept respectively). Combined
sirolimus + belatacept dramatically reduced proliferation (to
8%, favorably comparing with 13% Ki-67+ using tacrolimus/
MTX).
Sirolimus and belatacept also partially controlled T cell
cytotoxicity: While untreated aGvHD was associated
with excessive CD8+ granzyme B expression (82% granzyme
Bvery high vs 0.3% pre-transplant) sirolimus or belatacept
monotherapy partially controlled cytotoxicity (8% and 35 %
granzyme Bvery high with sirolimus or belatacept respec-
tively). Combination therapy dramatically reduced granzyme
Bvery high expression, to 1.5%, favorably comparing with 4%
using CNI/MTX.
The ability of sirolimus, belatacept, or the combination to
control Ki-67 and Granzyme B expression closely correlated
with survival (Figure 1B,C), and signiﬁcant co-expression of
granzyme B in the Ki-67+ cells was observed (Figure 1D),
suggesting that dual-positive Ki-67/Granzyme B cells may
mark a pathogenic population, amenable to tracking in the
peripheral blood.Implications: These results show, for the ﬁrst time, that
sirolimus and belatacept can combine synergistically to
control primate aGvHD. They also identify CD8+/Ki-67+/
Granzyme Bvery high dual-positive T cells as a potentially
sensitive biomarker of GvHD pathogenesis, amenable to
monitoring longitudinally in the blood.
Figure 1. Synergistic Control of Acute GvHD With Sirolimus + belatacept
(A) Dual therapy with sirolimus + belatacept synergistically prolongs survival
in a NHP aGvHD model.
(B) Proliferation, measured by Ki-67+ CD8+ T cells, correlates with clinical
aGvHD severity.
(C) Cytoxicity, measured by Granzyme B expression in CD8+ T cells, correlates
with clinical aGvHD severity.
(D) Signiﬁcant co-expression of KI-67 and Granzyme B in pathogenic CD8+ T
cells.
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Chronic graft versus host disease (cGvHD) remains
a major complication of allogeneic hematopoietic stem cell
transplantation (HSCT). At present, the immunopathophysi-
ology of cGVHD is not fully understood. A number of pre-
clinical and clinical studies support a role for B cell involve-
ment in the pathogenesis of cGvHD. Increased numbers of
CD21- B cell, believed to be immature/ transitional B cells,
were recently reported in the peripheral blood (PB) of cGvHD
patients. In this study, we report the expansion of a CD21- B
cell populationwith an exhausted phenotype in the memory
B cell compartment of patients with active cGVHD. Using
multicolor ﬂow cytometry we performed an extensive
anaylsis of B phenotype and function in 16 patients with
active cGvHD compared to 14 age-matched HSCT recipients
without clinical evidence of cGVHD and 11 healthy controls.
Chronic GvHD patients had signiﬁcantly higher frequencies
of CD21- B cells in the PB compared with patients without
cGvHD and HC (median 12.2% vs. 2.12% vs. 3%; P < 0.01).
Multi-parameter ﬂow cytometry revealed that the majority
of these cells were CD10- CD27- CD21‑ CD20hi, reminiscent
of the recently described exhausted B cells in HIV
patients with chronic viremia. We did not observe increased
transitional (CD24hi-CD38hi- CD19+) or immature B cells
(CD10+CD21-CD27-CD19+) in cGvHD patients compared with
patients with no cGVHD (median transitional 3.4% vs. 6.3%;
p¼0.08) and (median immature (out of total CD21- B cells)
